Trinordiol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trinordiol

Property Description
Active Ingredients Ethinyl Estradiol and Levonorgestrel
Form Oral tablet
Pharmacological Class Combined Oral Contraceptive (COC)
General Use Prevention of pregnancy (Contraception)
Origin Synthetic

What is the Pharmacological Class of Trinordiol?

Trinordiol is formally classified as a Combined Oral Contraceptive (COC), placing it within the high-level Hormonal Contraceptive group. This product is defined as an Estrogen-Progestin Combination. This classification indicates that the drug requires a specific blend of two hormone types to be effective. As a prescription-only medicine, the drug entity is an oral tablet that delivers two distinct types of synthetic steroidal hormones in a regulated cycle. These combined formulations are used as a method of birth control.

Composition and Triphasic Nature of Trinordiol

The formulation contains the International Nonproprietary Names (INN) Ethinyl Estradiol, which functions as a synthetic estrogen, and Levonorgestrel, which functions as a synthetic progestin. Both components are synthetic in origin. The pill is a combination product characterized by a triple-phased regimen (triphasic), meaning the quantities of the active ingredients are altered at three distinct points within the 21-day active cycle. This triphasic structure is a key feature that differentiates it from monophasic combined pills, which maintain a consistent hormonal dose. This approach is designed to approximate the hormonal shifts of the reproductive cycle.

Trinordiol’s General Purpose

The essential and singular purpose of this medication is the prevention of pregnancy (contraception). A typical use scenario involves reproductive-age women seeking a managed, non-surgical method of preventing conception. The combined action of the synthetic estrogen and progestin components suppresses the necessary biological events for conception. This hormonal contraceptive utilizes a managed internal approach to achieve its purpose by creating multiple defense barriers within the female reproductive system. The fundamental action of combined oral contraceptives is to inhibit ovulation.

Regulatory References

  1. DailyMed/FDA product labeling

What side effects are possible with Trinordiol?

Possible side effects and safety information

The official safety profile for Trinordiol, a combined oral contraceptive (COC), is structured around defining both expected hormonal effects and rare but serious cardiovascular risks, as documented in regulatory sources.

Serious Adverse Reactions

The most serious safety concerns cited prominently in official labeling relate to thromboembolic events. These include the documented risk of Venous Thromboembolism (VTE), such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), as well as Arterial Thromboembolism, which may manifest as stroke or myocardial infarction (heart attack). The labeling also notes concerns regarding the development of Liver Tumors (hepatic adenoma or malignant neoplasia) and Severe Hypertension.

Frequency-Classified Adverse Reactions

The majority of adverse reactions are non-serious and hormone-related. These effects are classified according to frequency in regulatory documents:

Classification Examples of Officially Listed Effects
Very Common Headache, Nausea, Lower abdominal pain
Common Vomiting, Breast tenderness, Weight gain, Acne, Depression/Mood changes
Uncommon Migraine, Fluid retention, Hypertension, Rash

Contextual Safety Patterns

The risk of Venous Thromboembolism is officially documented as highest during the first year of use or when restarting the medicine after a break of four weeks or more. Additionally, unscheduled bleeding and spotting are most frequently reported during the initial three months of use and may resolve over time.

Safety Considerations

Regulatory labeling specifies safety constraints for certain populations, particularly noting the increased risk of cardiovascular events in women over age 35 who smoke. Contraindications also exist for individuals with conditions such as severe liver disease, a history of migraine with aura, or known breast cancer.

Overdose and Emergency Response

The official regulatory profile for Trinordiol (Ethinyl Estradiol and Levonorgestrel) overdose is characterized by its low acute toxicity. Acute ingestion of large doses is generally not associated with serious or life-threatening adverse outcomes, according to government regulatory documentation.

Documented Manifestations and Emergency Action

If an overdose is suspected, the officially documented clinical manifestations may include non-severe symptoms such as nausea and vomiting. A common sign also listed is bleeding per vagina, which is classified as vaginal withdrawal bleeding. These manifestations reflect the physiological systems affected but do not typically indicate a severe systemic toxicity risk.

In the event of an acute overdose, regulatory guidance mandates that individuals seek medical attention immediately for review. While serious harm is not commonly reported for adults, a medical professional must be contacted for assessment of the patient's condition.

Management and Special Considerations

The official regulatory statement confirms that no specific antidote is known for overdose involving this combined oral contraceptive. Consequently, management is limited to providing symptomatic and supportive treatment based solely on the patient's clinical presentation.

A special consideration in the official labeling addresses accidental ingestion by young children. Regulatory documentation states that serious harmful effects have not been reported in young children following the accidental ingestion of these hormonal contraceptive tablets. Due to the low toxicity profile, general monitoring of vital signs may be required.

Therapeutic Uses of Trinordiol

Quick Facts

  • An available option for routine, ongoing pregnancy prevention.
  • Intended for use as a hormonal contraceptive to influence reproductive functions.

What Trinordiol Treats: Main Uses and Benefits

Trinordiol is a prescription medication indicated for use by individuals of reproductive potential to prevent pregnancy. This combined oral contraceptive may be an appropriate option for routine, ongoing birth control.

Its intended use is to help manage reproductive functions by influencing the natural process of the menstrual cycle to help reduce the chance of conception. When used as directed, combined oral contraceptives are a widely established method for family planning and contraceptive management.

Healthcare providers may suggest this medication as part of a therapeutic regimen to provide contraceptive reliability when taken consistently. Trinordiol is an available option that contributes to the management of reproductive health. The core purpose of the medication is to support the user's reproductive choices through daily hormonal therapy. It is important to remember that this medication does not protect against sexually transmitted infections (STIs).

Eligibility and Restrictions for Use

Trinordiol is indicated for use by females of reproductive potential (post-menarcheal women) for the prevention of pregnancy. The medicine's eligibility profile is strictly defined by absolute contraindications listed in official regulatory documents, primarily related to risk status.

Contraindicated Populations

Use is prohibited for patients with:

  • A high risk of arterial or venous thrombotic diseases, including a history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, or Myocardial Infarction (MI).
  • Known or suspected breast cancer or other estrogen-dependent malignancies.
  • Severe hepatic disease or liver tumors.
  • Uncontrolled hypertension or diabetes mellitus with vascular complications.
  • Migraine headaches with aura or other focal neurological symptoms.

Restricted and Conditional Use

Absolute non-eligibility applies to women over 35 years of age who smoke. Pregnancy is an absolute contraindication, and the medicine is not recommended for women who are breastfeeding. Furthermore, use must be discontinued at least four weeks before and through two weeks after major surgery associated with prolonged immobilization. Use is not indicated for pre-menarcheal or post-menopausal females.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for this combined oral contraceptive (Ethinyl Estradiol/Levonorgestrel) identifies specific interaction patterns that can alter its efficacy or compound certain safety risks. These patterns are generally classified as either pharmacokinetic interactions that change systemic drug exposure, or pharmacodynamic interactions that reinforce an effect.

Documented Interaction Restrictions

Co-administration is formally contraindicated with certain Hepatitis C combination drug regimens (including Ombitasvir/Paritaprevir/Ritonavir, and others), due to the documented risk of severe elevations in liver enzymes.

Usage is also restricted by non-drug factors; for instance, the medicine is contraindicated in women over the age of 35 who smoke, due to a substantially increased risk of serious cardiovascular events.

Exposure-Modifying Interactions

Interacting Agent Official Effect on Contraceptive Hormones
Enzyme Inducers (e.g., certain anticonvulsants) Decrease plasma concentrations, potentially diminishing efficacy.
Colesevelam Significantly reduces systemic exposure of Ethinyl Estradiol.
Grapefruit Juice May increase systemic exposure of the hormonal components.

Administration Requirements

When co-administering with Colesevelam, regulatory documentation requires that the two products be separated by 4 or more hours to mitigate the interaction that reduces hormonal exposure. Conditions that impair absorption, such as severe vomiting or diarrhea, are also officially noted as potentially leading to reduced systemic exposure of the active ingredients.

Mechanism of Action

Trinordiol is a combination of the synthetic hormones ethinylestradiol (estrogen component) and levonorgestrel (progestogen component), which modulate reproductive physiology across distinct biological systems.

Modulation of Hypothalamic-Pituitary Signaling

The synthetic hormones exert a negative feedback effect on the central regulatory axis. They act on the hypothalamus and pituitary gland to suppress the release of gonadotropin-releasing hormone (GnRH), as well as the pituitary hormones Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This suppression cascade results in the inhibition of follicular maturation and the Luteinizing Hormone (LH) surge.

Alteration of Endometrial and Cervical Biology

This mechanism involves direct local effects on reproductive tissues. The progestogen component, levonorgestrel, induces structural and secretory changes in the cervical mucus, causing it to become thicker and less permeable. Concurrently, the combined hormonal input leads to endometrial structural and functional modifications of the uterine lining.

Dosage and Administration Information

Trinordiol is designed for continuous, daily oral administration as an estrogen-progestin combination. The regimen is strictly cyclic, requiring the intake of one tablet daily for 28 consecutive days. The 28-day schedule consists of 21 active tablets followed by a 7-day period of either inactive tablets or a tablet-free interval. This standardized regimen is applicable to postmenarchal females of reproductive potential.

The most critical procedural requirement is that the active tablets must be consumed in the triphasic sequential order indicated on the package. These three phases contain varying microgram doses of levonorgestrel and ethinyl estradiol, and the prescribed order is essential for delivering the correct hormonal pattern across the 21 active days.

The standard protocol involves initiating the first tablet on Day 1 of the menstrual cycle (the first day of bleeding). Subsequent packs are started immediately after the 7-day interval is complete, irrespective of whether withdrawal bleeding has ceased. For consistent hormonal maintenance, the tablet must be taken at approximately the same time each day, often with liquid as needed.

Contraceptive efficacy may be compromised if the interval between doses exceeds 36 hours. The underlying principle for managing a missed dose is to ensure that the user does not exceed the maximum 7-day tablet-free interval and that a continuous run of seven uninterrupted active tablets is always established to maintain adequate hormonal suppression. This highly specific procedural structure governs the standardized use of the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trinordiol

This section describes the types of clinical and scientific research that have examined the combined oral contraceptive (COC) containing ethinyl estradiol and levonorgestrel, focusing on what was studied, the observed patterns, and what remains uncertain. The information here comes from official regulatory sources and peer-reviewed scientific literature.


Evidence for Use in Pregnancy Prevention (Contraception)

Clinical evidence for combined oral contraceptives (COCs) has primarily focused on assessing contraceptive outcomes. Randomized Controlled Trials (RCTs) and large-scale observational studies were the main methods used in research examining this formulation. In these studies, researchers observed populations of reproductive-age women (e.g., typically 18 to 35 years old). The studies monitored key outcomes, such as the contraceptive failure rate, and examined physical changes necessary for contraception, such as the inhibition of ovulation, through tracking hormone levels.

Studies designed to assess this effect reported measurements of contraceptive failure rates when combined oral contraceptives were used consistently. Clinical trial data described patterns of changes in hormone levels and follicular development across the observed treatment cycles. Research has also explored the triphasic (three-phased) formulation of this pill compared to fixed-dose (monophasic) COCs.

Evidence for Menstrual Cycle Regulation

Research has also explored the effects observed during combined oral contraceptive use on the menstrual cycle. Clinical trials monitored the patterns of cycle-related outcomes over multiple consecutive treatment cycles, recording outcomes related to cycle regularity, the duration of menses, and the presence of intermenstrual bleeding (spotting or breakthrough bleeding).

Findings described patterns of cycle length and consistency observed among the women studied. Clinical data also documented the incidence and frequency of spotting and breakthrough bleeding across the treatment period.

Research Gaps and Areas of Uncertainty

Research has explored the effects of this combined oral contraceptive, but several areas of uncertainty remain. Evidence remains limited to definitively determine whether the triphasic regimen type differs significantly from a monophasic regimen in terms of preventing pregnancy. Some limited studies observed some instances of less complete follicular suppression with the triphasic regimen during certain cycle weeks, indicating that certainty remains low regarding the clinical significance of this specific formulation difference. Furthermore, follow-up durations were limited in many of the key comparative trials, meaning that long-term effects are not fully established specifically regarding the nuanced differences between the various dosing structures. Findings describe group patterns, and research does not determine whether an individual will respond similarly to the patterns observed in the study populations.

Key Studies & References

  1. Ethinyl Estradiol and Levonorgestrel Combination Oral Contraceptives: MedlinePlus Drug Information
  2. Levonorgestrel and ethinyl estradiol tablets USP, triphasic regimen product labeling (DailyMed/FDA)

Frequently Asked Questions (FAQ)

Common questions about Trinordiol (FAQ)

Q: How is Trinordiol different from a monophasic pill?

Trinordiol is a triphasic pill, which is characterized by having three different phases of active tablets. Official product information indicates that the dosage of the hormones (levonorgestrel and ethinyl estradiol) varies across these three phases. In contrast, a monophasic oral contraceptive maintains the same hormone dose throughout the entire 21-day active cycle.

Q: When can I expect Trinordiol to start working?

Regulatory guidance suggests that contraceptive effectiveness is typically established after you have correctly taken seven consecutive active tablets. Regulatory guidance often notes that a non-hormonal backup method is recommended for the first seven days of the first cycle.

Q: Is it normal to have spotting or breakthrough bleeding on Trinordiol?

Yes, irregular vaginal bleeding, referred to as spotting or breakthrough bleeding, is a common experience reported in official product information. This is frequently seen during the initial three months of use as the body adjusts to the combined hormone levels.

Q: Are there any herbal supplements that should not be taken with Trinordiol?

Regulatory documents advise caution with certain herbal products. Specific regulatory warnings often single out the herbal supplement St. John's Wort. Official warnings indicate that this herb can decrease the concentration of contraceptive hormones in the body, which may potentially reduce the effectiveness of the pill.

Q: Can women over the age of 35 use Trinordiol?

Eligibility for use is highly conditional for women over the age of 35. The medicine is strictly contraindicated (prohibited) for women in this age group who smoke, due to a significantly increased risk of serious cardiovascular events, such as stroke or heart attack. For women over 35 who do not smoke, official documents describe that eligibility is conditional upon the absence of other specific risk factors.

Q: What is the risk of blood clots described in studies involving Trinordiol?

The risk of venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a known concern with combined oral contraceptives. Regulatory warnings specify that this risk is highest during the first year of use or when restarting the medicine after a break of four weeks or more.

Q: Why are there different colored pills in the Trinordiol pack?

The different colors (often light brown, white, and yellow) are a visual guide for the triphasic regimen. They correspond directly to the three different phases of active pills, each phase containing its own specific and varying hormone dosage of levonorgestrel and ethinyl estradiol.

Q: How quickly does fertility return after stopping Trinordiol?

Studies on combined oral contraceptives suggest that fertility typically returns relatively quickly after stopping the pill, often within the first few menstrual cycles. However, it may take several months for natural menstrual cycles to fully regulate and return to their pattern prior to starting the medication.

Q: How reliable is Trinordiol when used correctly?

According to official documentation, combined oral contraceptives are considered highly effective. The effectiveness rate when taken correctly is cited by regulatory agencies as being very high, often exceeding 99%.

Q: Are there different brand names for the same medicine as Trinordiol?

Yes, the triphasic combination of levonorgestrel and ethinyl estradiol is marketed under various brand names around the world. These include Triphasil, Trivora-28, and Enpresse, among others.

Q: Does Trinordiol help with conditions other than preventing pregnancy?

The primary and only officially indicated use of Trinordiol is for the prevention of pregnancy. However, this combination has been studied for use in helping manage symptoms associated with heavy or irregular menstruation and moderate acne.

Q: Do many users experience changes in mood while taking Trinordiol?

Changes in mood, including depression, are officially listed as a 'Common' side effect in regulatory documents. This indicates that up to 1 in 10 users may experience this effect.

Q: What types of antibiotics are known to interact with Trinordiol?

Official product information notes that certain antibiotics can interact with the pill. Specific broad-spectrum antibacterials, like amoxicillin, have been documented as potentially reducing the pill's effectiveness. Regulatory guidance notes this interaction may require the use of an additional barrier method for contraceptive protection.

Q: Is there information available on using Trinordiol while breastfeeding?

Regulatory guidance generally advises against using this medication while breastfeeding, especially shortly after giving birth. This is because the estrogen component has the potential to suppress the quantity and quality of breast milk (known as suppressing lactation).

Q: Does Trinordiol protect against sexually transmitted infections?

No. Official patient information clearly states that Trinordiol, like all birth control pills, does not protect against HIV infection (AIDS) or any other sexually transmitted infections (STIs).

Q: What should I do if I miss a non-active pill?

Missing an inactive (placebo) tablet does not reduce contraceptive protection, as these pills contain no hormones. Regulatory documents indicate that the missed inactive pill can be discarded, and the user should proceed to start the next active pack on schedule.

Q: What happens if you stop taking Trinordiol suddenly?

When you stop taking the pill, the sudden decrease in synthetic hormones typically causes a withdrawal bleed. It may take several months for the body’s natural hormonal cycle to re-establish and for regular, natural menstruation to return to the pattern observed before starting the pill.

Q: Is it possible to take Trinordiol for many years?

Many women use oral contraceptives long-term. However, regulatory warnings note that the risk of certain rare conditions, such as liver tumors (hepatic neoplasms), is associated with prolonged use, typically defined as four or more years.

Q: Are there any long-term health concerns described in the research for Trinordiol?

Serious long-term risks documented in regulatory warnings are primarily cardiovascular, including the potential for thromboembolic events, stroke, and heart attack, and hepatic risks (liver tumors). Official documents describe that the overall incidence of these serious events remains low, but regulatory sources note the importance of considering these risk factors, which are often cited as increasing over time and with age.

Q: Is it possible that Trinordiol will stop my period completely?

Yes, amenorrhea (the absence of menstruation) during the inactive pill week is listed in regulatory documents as a possible side effect. Official guidance notes that if this absence of bleeding persists for two or more cycles, the possibility of pregnancy is typically assessed.

Q: Does studies suggest Trinordiol is less effective if taken with food?

Official regulatory guidance focuses on conditions that impair absorption, such as severe vomiting or diarrhea, which can reduce efficacy. There are no specific warnings stating that taking the pill with food generally affects its effectiveness.

Q: Is Trinordiol a generic version of another drug?

No, Trinordiol is a brand-name medicine. However, the combination of its active ingredients, levonorgestrel and ethinyl estradiol, is widely available generically and under many other brand names.

Q: Is nausea a temporary side effect when first starting Trinordiol?

Nausea is a 'Very Common' side effect listed in official safety information. Although not explicitly stated as temporary, many common hormonal side effects, such as unscheduled bleeding, are noted to typically resolve during the initial three months of adjustment as the body gets used to the medication.

Q: Can grapefruit juice interfere with how Trinordiol works?

Yes. Regulatory interaction documentation indicates that consuming grapefruit juice may increase the systemic exposure (level) of the hormonal components in the blood. This pharmacokinetic change could potentially lead to an increase in hormone-related side effects.

Q: Are there specific medical tests required before starting Trinordiol?

Official guidance requires a thorough health history and a physical examination, including measuring blood pressure, before starting and during the use of the medication. Regular breast and pelvic exams and a Pap smear are also often recommended by healthcare professionals.

Q: Is there a generic equivalent available for Trinordiol?

Yes, the combination of levonorgestrel and ethinyl estradiol in a triphasic regimen is available as a generic equivalent in addition to other brand names.

Q: What is the common dosage of hormones in the different phases of Trinordiol?

Trinordiol is a triphasic pill, meaning the hormone dose changes throughout the 21 active tablets. The three phases contain distinct, varying amounts of levonorgestrel and ethinyl estradiol, which are specified in the official product information.

Q: Does research indicate Trinordiol affects bone density?

Research has investigated the link between combination oral contraceptives and bone mineral density (BMD). While findings are complex, some studies suggest that combined hormonal contraceptives may be associated with a potential for slower BMD accrual, particularly in adolescents, and this area is actively monitored.

Q: Does Trinordiol influence the results of any common lab tests?

Yes, official safety information indicates that taking combined oral contraceptives is known to influence the results of several lab tests. This includes tests for liver function, thyroid function, blood clotting (coagulation), and lipid metabolism, so the administering lab should be informed of pill use.

Q: Why is it important to take the pills in the correct order for Trinordiol?

Taking the pills in the correct sequence is essential because Trinordiol is a triphasic pill where the hormone dose changes daily. Taking them out of order disrupts the intended sequential delivery of hormones across the cycle, which may compromise contraceptive protection.

How should Trinordiol be stored and disposed of?

The storage and disposal of Trinordiol (levonorgestrel/ethinyl estradiol) must follow specific requirements set by regulatory agencies to maintain the product's quality and ensure safety.

Storage & Disposal Requirement Official Regulatory Mandate
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Environmental Protection Keep away from excess heat, moisture, and direct light. The product must be kept from freezing.
Packaging Keep the medication in the container it came in, tightly closed, and in the original package.
Child Safety Keep out of the sight and reach of children due to the potential risk of accidental hormonal exposure.
Disposal Unused or expired medication must be disposed of in accordance with local requirements; do not throw into wastewater.

These mandates structure the official profile by defining that the tablets must be physically protected within their original packaging under controlled environmental conditions. Proper disposal is required to prevent environmental contamination and accidental ingestion of unneeded medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trinordiol found in:

A-Z Index: